iX Biopharma Announces S\$6 Million Fundraising via Proposed Placement – Receives SGX-ST In-Principle Approval

Key Highlights

• Gross Proceeds: iX Biopharma Ltd. plans to raise no less than S\$6,000,000 through a proposed placement.
• Placement Agreement: The company has entered into a placement agreement with Oversea-Chinese Banking Corporation Limited (OCBC Bank).
• Listing Approval: The Singapore Exchange Securities Trading Limited (SGX-ST) has granted in-principle approval for the listing and quotation of up to 75,800,000 new shares arising from the placement.
• Date of Approval: iX Biopharma received the SGX-ST’s in-principle approval on 19 February 2026.
• Conditions Apply: The placement is still subject to the fulfilment of various conditions as stipulated in the placement agreement and compliance with SGX-ST listing requirements.

Details Investors Should Know

The proposed placement is a significant corporate action for iX Biopharma Ltd., which aims to raise substantial capital to support its business objectives. This move could have a direct impact on the company’s share price and valuation for several reasons:

1. Dilution of Shares: The issuance of up to 75,800,000 new shares will increase the total share base and may dilute existing shareholders. Investors should assess how this dilution might affect their holdings and the company’s earnings per share.
2. Fund Usage: While the specific use of proceeds was not detailed in the announcement, such capital injections are typically aimed at driving growth, funding R&D, or supporting expansion plans, which could positively influence future prospects.
3. Regulatory Compliance: The in-principle approval from SGX-ST is conditional and does not represent a final endorsement of the company or its shares. Completion of the placement remains dependent on satisfaction of the placement agreement’s conditions and SGX-ST’s requirements.
4. Trading Caution: Management has advised shareholders and potential investors to exercise caution when trading iX Biopharma shares, given the uncertainties and conditions surrounding the placement. Those unsure of their next steps should consult professional advisors.
5. Further Updates: The company has committed to keeping shareholders informed of all significant developments and progress related to the placement.

Other Important Information

• Not for US Distribution: The new shares have not been, and will not be, registered under the U.S. Securities Act of 1933 or the securities laws of any U.S. state. As such, these shares cannot be offered or sold in the United States except in certain exempted transactions.
• Sponsor’s Statement: The announcement was reviewed by UOB Kay Hian Private Limited, iX Biopharma’s sponsor, but neither the sponsor nor the SGX-ST assumes responsibility for the contents of the announcement.
• Contact Information: For further queries, the contact person is Mr. Lance Tan, Senior Vice President, UOB Kay Hian, at their Singapore office.

Potential Price Sensitivity

This announcement is potentially price sensitive for iX Biopharma’s shares due to the following reasons:

• It directly impacts the company’s capital structure.
• The placement could enable new strategic initiatives or expansion.
• Share dilution may affect per-share metrics and investor valuations.
• Completion and timing of the placement, as well as market reaction to the news, could drive volatility in the short term.

Investors are advised to monitor subsequent updates and exercise appropriate caution.

Disclaimer

This article is for informational purposes only and does not constitute investment advice. Investors should conduct their own due diligence or consult professional financial advisers before making any investment decisions. The Singapore Exchange Securities Trading Limited assumes no responsibility for the contents of this article.

View IX BiopharmaW260718 Historical chart here